Retifanlimab
Human Papillomavirus-Related Squamous Cell Carcinoma
Explore 17 assets in Human Papillomavirus-Related Squamous Cell Carcinoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Jennifer Dorth
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07425054CT.gov ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Human Papillomavirus-Related Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retifanlimab (this asset) | Jennifer Dorth | P2 | CCC · 53 |
| Cyclophosphamide | Christian Hinrichs | P2 | B |
| Fludarabine | Christian Hinrichs | P2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| 9-valent human papillomavirus recombinant vaccine | Shanghai Bovax Biotechnology Co., Ltd. | P3 | B |
| scg142 | SCG Cell Therapy Pte. Ltd. | P1/2 | CCC |
| Regorafenib | Institut Bergonié | P1/2 | CC |
| Alpelisib | Pamela Munster | P1 | CC |
| scg142 tcr-t cells | The Affiliated Hospital of Qingdao University | P1 | CC |
+10 more in the Human Papillomavirus-Related Squamous Cell Carcinoma cohort
Other indications for Retifanlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anal Canal Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Urothelial Carcinoma | — | P2 | BB · 66 |
| Renal Cell Carcinoma | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retifanlimab in Human Papillomavirus-Related Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retifanlimab-human-papillomavirus-related-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →